According to the Zhitong Finance App, Kehua Biotech (002022.SZ) released its 2023 semi-annual report. During the reporting period, the company achieved operating income of 1,396 billion yuan, an increase of 54.66% over the previous year. Net profit attributable to shareholders of listed companies was RMB 21,1281 million, a year-on-year decrease of 54.50%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was achieved at 6.8851 million yuan, a year-on-year decrease of 84.63%. The basic earnings per share were $0.0411.

The report shows that the reason for the increase in operating income: according to data for the same period last year, Tianlong Company was not included in the scope of the merger; main revenue and gross margin declined due to factors such as changes in the market environment, increased industry competition, and implementation of collection policies.